• Eli Lilly's selpercatinib (Retevmo) has received full FDA approval for the treatment of solid tumors with RET gene fusions.
• The approval covers both adult and pediatric patients, expanding access beyond earlier indications.
• This decision further builds out Eli Lilly's oncology portfolio alongside its established presence in diabetes and obesity treatments.

Eli Lilly (NYSE:LLY) now has a fully approved targeted cancer therapy that addresses solid tumors driven by RET gene fusions, an area where patients often face limited choices. The stock trades at $1,152.54, with a 1 year return of 50.4% and a 3 year return of 160.9%, alongside a 5 year gain of more than 4x. This new approval adds a distinct oncology pillar to a company more commonly associated with metabolic drugs.

For investors tracking Eli Lilly, the full FDA approval of Retevmo helps clarify the role oncology may play alongside existing franchises. While the long term financial impact is uncertain, the broader label could influence how the market views the balance of Eli Lilly's growth drivers across different therapy areas.

Stay updated on the most important news stories for Eli Lilly by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Eli Lilly.

The full FDA approval of selpercatinib for RET fusion positive solid tumors gives Eli Lilly a wider oncology foothold alongside its GLP 1 driven obesity and diabetes portfolio. Retevmo now reaches both adult and pediatric patients with locally advanced or metastatic disease who have either exhausted prior systemic therapies or lack alternatives, which broadens the potential treated population across multiple tumor types. For you as an investor, this matters because Lilly is heavily concentrated in Mounjaro, Zepbound and Foundayo, and oncology can act as an additional revenue pillar that is less tied to reimbursement debates in obesity. It also places Lilly more directly against oncology focused peers such as Roche, Novartis and AstraZeneca in precision medicine, where targeted therapies can support premium pricing and longer product lifecycles.

How This Fits Into The Eli Lilly Narrative

• The approval supports the narrative that Eli Lilly is building out high value specialty drugs beyond GLP 1s, aligning with expectations that a broader mix of therapies can underpin long term earnings growth.
• It partly challenges the idea that Lilly is overly reliant on a narrow portfolio, but does not remove concerns in the narrative about exposure to pricing and reimbursement pressure in obesity and diabetes.
• The focus of the narrative is on incretin drugs and manufacturing expansion, so the expanded tumor agnostic label for Retevmo may not be fully reflected in how investors are thinking about future contributions from oncology.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Eli Lilly to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Analysts have flagged that Eli Lilly carries a high level of debt, so funding oncology expansion alongside obesity and diabetes launches could raise balance sheet risk if cash flows soften.
• ⚠️ High levels of non cash earnings point to accounting complexity, which can make it harder for you to judge how much underlying profit is coming from products like Retevmo versus one off items.
• 🎁 Earnings grew very strongly over the past year, which suggests Eli Lilly currently has financial capacity to support additional oncology investments and post approval studies around Retevmo.
• 🎁 Earnings are forecast to grow at a double digit rate, and Retevmo adds another source of potential contribution that is not directly tied to GLP 1 prescription trends or obesity reimbursement decisions.

What To Watch Going Forward

From here, keep an eye on how quickly Retevmo uptake builds across community oncology and major cancer centers, and whether payers in the US and key ex US markets support broad reimbursement for RET fusion positive solid tumors. It is also worth tracking how management talks about oncology in upcoming earnings, including any commentary on Retevmo’s share within the RET space relative to therapies from competitors such as Roche or Novartis. Finally, watch for updated analyst commentary on Eli Lilly that explicitly factors Retevmo into revenue mix expectations, not just GLP 1 trends, as that can influence how the stock’s premium valuation is viewed.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Eli Lilly, head to the community page for Eli Lilly to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.